Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma

Abstract

Hybrids, which were composed of the amphiphilic diblock copolymer polystyrene‐b‐poly(2‐hydroxylethyl methacrylate) (PSt‐b‐PHEMA) and nickel, cobalt, or a nickel–cobalt alloy, were characterized with infrared absorption spectroscopy and ultraviolet–visible (UV–vis) absorption spectroscopy. UV–vis spectroscopy analysis showed that a redshift happened after the PSt‐b‐PHEMA/metal‐ion complexes were reduced by KBH4. The PSt‐b‐PHEMA/nickel–cobalt alloy hybrids had the biggest redshift [difference of the UV‐vis absorption wavelength between (PSt‐b‐PHEMA)/metal ion complex and (PSt‐b‐PHEMA)/metal hybrids (Δλm = 19.9 nm)]. In comparison with the PSt‐b‐PHEMA/nickel hybrids (Δλm = 3.5 nm) and PSt‐b‐PHEMA/cobalt hybrids (Δλm = 9.0 nm). The magnetic properties of PSt‐b‐PHEMA/metal were studied with vibrating sample magnetometry. The results of magnetic hysteresis loop studies showed that the obtained PSt‐b‐PHEMA/metal hybrids could be categorized as ferromagnetic materials. The results showed that the magnetic susceptibility decreased with increasing temperature in the range of 150–400 K and increased with increasing temperature above 400 K. © 2005 Wiley Periodicals, Inc. J Appl Polym Sci, 2006

HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review

“…However, they also found that higher expression level of HMGB1 was significantly associated with a poorer prognosis. At the same time, Takeuchi et al [51] demonstrated that overexpression of RAGE, one of HMGB1′s receptors, was associated with subsequent recurrence, lung metastasis, and poor survival in chondrosarcoma. A recent meta-analysis also showed higher expression of C-X-C chemokine receptor 4 (CXCR4), another HMGB1′s receptor, indicated poorer prognosis in various types of cancer [2].…”

Preoperative radiographic and histopathologic evaluation of central chondrosarcoma

“…Takeuchi et al [28] demonstrated that significant differences in the endogenous secretory receptor for advanced glycation end products (esRAGE) labeling index were seen between grade 1 and grade 2 chondrosarcomas using an enzyme-linked immunosorbent assay (ELISA) in 11 cases of chondrosarcoma. However, further large-scale prospective studies are required to validate these markers as routine diagnostic and prognostic tools in the assessment of chondrosarcoma.…”

Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms

“…On the other hand blocking of the binding of the RAGE ligand HMGB1 to the receptor by using RAGE variants lacking the cytosolic or transmembrane domains, strongly inhibited the metastatic behaviour of glioma cells in terms of invasive growth, motility and migration (Taguchi et al, 2000). A recent study based on immunohistologic analyses reports a correlation of esRAGE and staging of chondrosarcomas classifying RAGE expression as tumourmarker for malignancy (Takeuchi et al, 2007).…”

“…In spite of its obvious relationship to cancer and metastasis data focusing soluble RAGE deregulations or structural aberrations and tumours is currently rare. Only recently Takeuchi et al reported a correlation between esRAGE, RAGE, and HMGB1 and staging of chondrosarcomas classifying esRAGE expression as tumourmarker for malignancy (Takeuchi et al, 2007).…”